These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

719 related items for PubMed ID: 17973898

  • 1. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM, García-Horsman JA, Piltonen M, Huotari M, Männistö PT.
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [Abstract] [Full Text] [Related]

  • 2. L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
    Kääriäinen TM, García-Horsman JA, Piltonen M, Männistö PT.
    Neuroreport; 2009 Feb 18; 20(3):313-8. PubMed ID: 19188858
    [Abstract] [Full Text] [Related]

  • 3. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA, Weiner N.
    J Pharmacol Exp Ther; 1993 Dec 18; 267(3):1105-11. PubMed ID: 8263772
    [Abstract] [Full Text] [Related]

  • 4. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 18; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 5. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS, Starr MS.
    Synapse; 1999 Oct 18; 34(1):36-46. PubMed ID: 10459170
    [Abstract] [Full Text] [Related]

  • 6. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R.
    Neurosci Res; 2007 Sep 18; 59(1):1-7. PubMed ID: 17586078
    [Abstract] [Full Text] [Related]

  • 7. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM, Delville Y, Schallert T.
    Behav Brain Res; 2005 Jan 30; 156(2):201-13. PubMed ID: 15582106
    [Abstract] [Full Text] [Related]

  • 8. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA.
    Neurobiol Dis; 2011 Jun 30; 42(3):327-40. PubMed ID: 21310234
    [Abstract] [Full Text] [Related]

  • 9. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ.
    Exp Neurol; 2000 Jan 30; 161(1):212-9. PubMed ID: 10683287
    [Abstract] [Full Text] [Related]

  • 10. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study.
    Boulamery A, Simon N, Vidal J, Bruguerolle B.
    Chronobiol Int; 2010 Jan 30; 27(2):251-64. PubMed ID: 20370468
    [Abstract] [Full Text] [Related]

  • 11. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL, Kelly AM, Kennedy GA.
    Behav Brain Res; 2008 Nov 03; 193(1):37-47. PubMed ID: 18547659
    [Abstract] [Full Text] [Related]

  • 12. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
    Aguiar LM, Macêdo DS, Vasconcelos SM, Oliveira AA, de Sousa FC, Viana GS.
    Brain Res; 2008 Jan 29; 1191():192-9. PubMed ID: 18164694
    [Abstract] [Full Text] [Related]

  • 13. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
    Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F.
    J Neurochem; 2005 Apr 29; 93(1):94-104. PubMed ID: 15773909
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.
    Neurobiol Dis; 2006 May 29; 22(2):421-34. PubMed ID: 16480889
    [Abstract] [Full Text] [Related]

  • 15. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
    Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA.
    J Neurochem; 2006 Mar 29; 96(6):1718-27. PubMed ID: 16539687
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 17. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB, Murrin LC, Pfeiffer RF, Deupree JD.
    Clin Neuropharmacol; 1984 Aug 30; 7(3):247-57. PubMed ID: 6435870
    [Abstract] [Full Text] [Related]

  • 18. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease?
    Lane EL, Cheetham SC, Jenner P.
    Exp Neurol; 2006 Feb 30; 197(2):284-90. PubMed ID: 16005456
    [Abstract] [Full Text] [Related]

  • 19. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
    Fang C, Yin J, Xu Z, Wang Y, Xu H, Zhou H, Gao C.
    Cell Biochem Biophys; 2011 Jan 30; 59(1):49-56. PubMed ID: 20714825
    [Abstract] [Full Text] [Related]

  • 20. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
    Lorenc-Koci E, Czarnecka A, Lenda T, Kamińska K, Konieczny J.
    Neurochem Int; 2013 Dec 30; 63(8):790-804. PubMed ID: 24090640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.